Free Trial
Evan David

Evan David Analyst Performance

Managing Director & Head of Healthcare Research at BMO Capital Markets

Evan David is a stock analyst at BMO Capital Markets in the medical sector, covering 6 publicly traded companies. Over the past year, Evan David has issued 14 stock ratings, including buy and hold recommendations. While full access to Evan David's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Evan David's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
14 Last 0 Years
Buy Recommendations
69.23% 9 Buy Ratings
Companies Covered
6 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy69.2%9 ratings
Hold30.8%4 ratings
Sell0.0%0 ratings

Out of 13 total stock ratings issued by Evan David at BMO Capital Markets, the majority (69.2%) have been Buy recommendations, followed by 30.8% Hold.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

ExchangePercentageCount
NYSE
50.0% of companies on NYSE
3 companies
NASDAQ
50.0% of companies on NASDAQ
3 companies

Evan David, an analyst at BMO Capital Markets, currently covers 6 companies listed on NYSE and NASDAQ, with the majority traded on NYSE.

Coverage Focus

Sector IconSectorPercentage
Medical
6 companies
100.0%

Evan David of BMO Capital Markets specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
LARGE CAP PHARMA
3 companies
50.0%
MED - BIOMED/GENE
3 companies
50.0%

About Evan David

Evan is a Managing Director and Head of Healthcare Research at BMO Capital Markets. He is also the firm’s Senior Research Analyst covering Pharmaceuticals and Biotechnology companies. Prior to joining BMO, Evan was a Senior Research Analyst at Credit Suisse, covering BioPharma companies. He started his Wall Street Career at Deutsche Bank and later was on the #2 Institutional Investor ranked Biopharma team at Barclays. Before equity research, Evan was a strategy consultant for the BioPharma industry. Evan is consistently recognized as a top research analyst and leading voice on the sector. Among his achievements, he hosted the first obesity and metabolic disease focused investor conference in 2024. In 2021, he was named a Rising Star of Equity Research by Business Insider. He is regularly a guest on CNBC’s Fast Money, Squawk Box, and Power Lunch; Yahoo Finance and Canada’s BNN Bloomberg. He is also frequently quoted in The Wall Street Journal, The Financial Times, The New York Times, and industry trade publications. Evan holds a BBA in Finance and Accounting and BA in Spanish, both from the University of Michigan.
Follow on LinkedIn

Evan David's Ratings History at BMO Capital Markets

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
AbbVie Inc. stock logo
ABBV
AbbVie
3/9/2026Reiterated Rating$223.71Outperform
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
2/17/2026Lower Price Target$55.99$100.00Outperform
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
1/26/2026Boost Price Target$135.93$150.00Outperform
AbbVie Inc. stock logo
ABBV
AbbVie
1/15/2026Reiterated Rating$217.78$258.00Outperform
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
1/14/2026Reiterated Rating$59.57Market Perform
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
1/13/2026Reiterated Rating$123.67Outperform
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
12/23/2025Reiterated Rating$52.07Market Perform
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
12/18/2025Upgrade$99.19$130.00Outperform
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
12/4/2025Boost Price Target$723.67$850.00Outperform
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
11/25/2025Set Price Target$126.99$135.00
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
11/25/2025Lower Price Target$44.99$46.00Market Perform
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
11/17/2025Reiterated Rating$48.58Market Perform
AbbVie Inc. stock logo
ABBV
AbbVie
9/12/2025Boost Price Target$220.09$240.00Outperform
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
8/4/2025Boost Price Target$567.14$640.00Outperform